EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors

Matthew J Townsend iD, Isaac J Benque, Michael Li, Shilpa Grover iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17980 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Matthew J Townsend und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University Hospital, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Gastrointestinal Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 164 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are effective oncologic agents which frequently cause immune‐related adverse events (irAEs) which can impact multiple organ systems. Onco‐Gastroenterology is a novel and emerging subspecialty within gastroenterology focused on cancer treatment‐related complications. Gastroenterologists must be prepared to identify and manage diverse immune‐mediated toxicities including enterocolitis, hepatitis, pancreatitis and other ICI‐induced toxicities.

Aim

To provide a narrative review of the epidemiology, diagnostic evaluation and management of checkpoint inhibitor‐induced gastrointestinal and hepatic toxicities.

Methods

We searched Cochrane and PubMed databases for articles published through August 2023.

Results

Gastrointestinal and hepatic irAEs include most commonly enterocolitis and hepatitis, but also pancreatitis, oesophagitis, gastritis, motility disorders (gastroparesis) and other rarer toxicities. Guidelines from the National Comprehensive Cancer Network, American Society of Clinical Oncology and European Society for Medical Oncology, in combination with emerging cohort and clinical trial data, offer strategies for management of ICI toxicities. Evaluation of irAEs severity by formal classification and clinical stability, and a thorough workup for alternative etiologies which may clinically mimic irAEs underlie initial management. Treatments include corticosteroids, biologics and other immunosuppressive agents plus supportive care; decisions on dosing, timing and choice of steroid adjuncts and potential for subsequent checkpoint inhibitor dosing are nuanced and toxicity‐specific.

Conclusions

Expanding clinical trial and cohort data have clarified the epidemiology and clinical characteristics of gastrointestinal, pancreatic and hepatic toxicities of ICIs. Guidelines, though valuable, remain based principally on retrospective cohort data. Quality prospective, controlled studies may refine algorithms for treatment and potential immunotherapy rechallenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsGastrointestinal DiseasesHumansNeoplasmsChemical and Drug Induced Liver InjuryPancreatitis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Duke University Hospital, Durham, North Carolina, USA.
  • University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Division of Gastroenterology, University of California San Francisco Medical Center, San Francisco, California, USA.
  • Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Matthew J Townsend, Shilpa Grover

Zitieren

APA

Townsend, M. J., Benque, I. J., Li, M., & Grover, S. (2024). Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17980

Vancouver

Townsend MJ, Benque IJ, Li M, Grover S. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17980

BibTeX
@article{Townsend2024,
  author = {Townsend, Matthew J and Benque, Isaac J and Li, Michael and Grover, Shilpa},
  title = {Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17980}
}
Kostenlos starten →